Zentalis Pharmaceuticals’ (ZNTL) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a report issued on Monday morning, Benzinga reports. The firm currently has a $20.00 price objective on the stock. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q3 2024 earnings at ($0.96) EPS, Q4 2024 earnings at ($1.01) EPS, FY2024 earnings at ($3.06) EPS, FY2025 earnings at ($3.74) EPS, FY2026 earnings at ($3.74) EPS, FY2027 earnings at ($3.45) EPS and FY2028 earnings at ($2.34) EPS.

A number of other research analysts also recently weighed in on the stock. Morgan Stanley reissued an equal weight rating and set a $8.00 target price (down from $38.00) on shares of Zentalis Pharmaceuticals in a research report on Tuesday, June 18th. Jefferies Financial Group reissued a hold rating and issued a $6.00 target price (down from $42.00) on shares of Zentalis Pharmaceuticals in a research report on Tuesday, June 18th. UBS Group cut Zentalis Pharmaceuticals from a buy rating to a neutral rating and dropped their price target for the company from $28.00 to $5.00 in a research report on Thursday, June 20th. Stifel Nicolaus lowered their price objective on Zentalis Pharmaceuticals from $32.00 to $10.00 and set a buy rating on the stock in a research note on Tuesday, June 18th. Finally, Wedbush lowered shares of Zentalis Pharmaceuticals from a neutral rating to an underperform rating and cut their target price for the stock from $15.00 to $4.00 in a research report on Tuesday, June 18th. Seven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of Hold and an average price target of $11.33.

Zentalis Pharmaceuticals Stock Up 10.5 %

Shares of NASDAQ:ZNTL opened at $3.20 on Monday. The stock’s 50 day moving average is $4.72 and its 200-day moving average is $10.12. Zentalis Pharmaceuticals has a twelve month low of $2.83 and a twelve month high of $27.79. The firm has a market capitalization of $227.28 million, a price-to-earnings ratio of -0.96 and a beta of 1.70.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Friday, August 9th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.40). During the same period last year, the company posted ($1.85) earnings per share. Equities research analysts anticipate that Zentalis Pharmaceuticals will post -2.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Zentalis Pharmaceuticals

In related news, CFO Cam Gallagher sold 9,597 shares of the business’s stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $11.98, for a total transaction of $114,972.06. Following the completion of the transaction, the chief financial officer now owns 633,680 shares of the company’s stock, valued at $7,591,486.40. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Eventide Asset Management LLC lifted its position in Zentalis Pharmaceuticals by 47.9% during the fourth quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock valued at $175,134,000 after purchasing an additional 3,745,936 shares during the last quarter. Decheng Capital LLC purchased a new position in Zentalis Pharmaceuticals in the fourth quarter worth $31,809,000. Price T Rowe Associates Inc. MD increased its stake in Zentalis Pharmaceuticals by 20.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock valued at $54,999,000 after acquiring an additional 585,644 shares during the last quarter. Renaissance Technologies LLC increased its stake in Zentalis Pharmaceuticals by 152.6% in the second quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock valued at $2,706,000 after acquiring an additional 399,745 shares during the last quarter. Finally, Federated Hermes Inc. raised its position in Zentalis Pharmaceuticals by 10.9% during the fourth quarter. Federated Hermes Inc. now owns 2,160,565 shares of the company’s stock valued at $32,733,000 after purchasing an additional 212,872 shares in the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.